Drug intelligence / Profile preview

kb16a

Development stage: Preclinical
Lead developer: KBio
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

KB16A is a monoclonal antibody developed by KBio Inc. It acts as an inhibitor of LILRB2 (Leukocyte immunoglobulin-like receptor subfamily B member 2), targeting the immune checkpoint pathway. The primary therapeutic area is neoplasms, with its highest R&D status currently at preclinical. The drug is designed for immuno-oncology applications and has shown initial positive in vivo data[1][2].

Other names: KB-16AKB16AKB 16A

Targets

LILRB2 (Leukocyte immunoglobulin-like receptor subfamily B member 2)

Beyond the preview

Go deeper on kb16a.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on kb16a.

Explore the full profile